The ARHGAP1 Knockout A-549 Polyclonal Cells product comprises a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A?549 human lung adenocarcinoma cell line. This population carries a targeted disruption of the ARHGAP1 gene, enabling loss-of-function studies in a physiologically relevant cancer model. The polyclonal format maintains genetic heterogeneity while uniformly ablating ARHGAP1 expression, providing a robust tool for functional genomics and cancer biology investigations.
The parental A?549 cell line is an epithelial cell model originally established from a human lung adenocarcinoma. As one of the most widely used non?small?cell lung cancer (NSCLC) lines, A?549 recapitulates key features of adenocarcinoma, including epithelial morphology, anchorage?independent growth, and tumorigenicity in xenograft models. It serves as a standard platform for studying oncogenic signaling, drug response, and metastatic mechanisms, making it an ideal host for gene knockout studies.
ARHGAP1 encodes a Rho GTPase?activating protein that accelerates GTP hydrolysis on RhoA, Cdc42, and Rac1, converting them to their inactive GDP?bound states. This activity negatively regulates downstream effectors including ROCK, mDia, PAK, and WAVE, thereby restraining actin polymerization, stress fiber formation, and cell contraction. ARHGAP1 is activated by upstream signals such as integrin clustering and epidermal growth factor receptor (EGFR) engagement, and its localization and activity are modulated by interactions with paxillin and focal adhesion kinase (FAK) at sites of cell adhesion. Through these interactions, ARHGAP1 integrates mechanical and chemical cues to control cytoskeletal dynamics and cell motility.
In the context of A?549 lung adenocarcinoma cells, loss of ARHGAP1 is expected to elevate the levels of active GTP?bound RhoA, Cdc42, and Rac1, leading to enhanced stress fiber assembly, increased actomyosin contractility, and heightened migratory and invasive capacity. This phenotype mirrors processes critical to tumor cell invasion and metastasis, positioning the ARHGAP1 knockout model as a valuable system for dissecting the molecular determinants of lung cancer progression. Furthermore, it enables the study of how Rho GTPase hyperactivation influences sensitivity to chemotherapeutics or targeted agents.
The ARHGAP1 Knockout A?549 Polyclonal Cells support a wide range of applications, including the investigation of Rho GTPase signaling networks, cancer cell migration and invasion assays (scratch wound healing, transwell), cytoskeletal organization studies via phalloidin staining, and focal adhesion dynamics using paxillin or vinculin immunofluorescence. These cells are also suitable for drug sensitivity screening, RNA?seq transcriptomic profiling, and functional complementation experiments. For further information or to request a quotation, please contact Ascent Research.
